FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
H.C. Wainwright Starts FibroBiologics (FBLG) at Buy
October 30, 2024 7:55 AM EDTH.C. Wainwright analyst Matthew Caufield initiates coverage on FibroBiologics (NASDAQ: FBLG) with a Buy rating and a price target of $12.00.
The analyst comments "Fibroblast cellular therapieslooking first to diabetic foot ulcer indication as main focus. FibroBiologics, Inc. is a clinical stage biotechnology company focused on development of fibroblast cellular therapies for chronic diseases. The companys extensive US and... More
